Intellia Therapeutics (NTLA) Tops Q3 EPS by 12c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
Intellia Therapeutics Announces Third Quarter 2020 Financial Results
November 5, 2020 7:30 AM ESTOn track to dose first patient by year-end with NTLA-2001 for the treatment of transthyretin amyloidosis (ATTR), following regulatory authorization to initiate Phase 1 clinical trial Anticipates submitting an IND or IND-equivalent for lead TCR-T cell therapy, NTLA-5001 for the treatment of acute myeloid leukemia (AML), in 1H 2021Expects to submit an IND or IND-equivalent... More
